IMAB

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation
Earnings

High

1.0792

Open

1.020

VWAP

1.05

Vol

184.47K

Mkt Cap

80.84M

Low

0.980

Amount

193.21K

EV/EBITDA(TTM)

Total Shares

80.88M

-87.78M

EV/OCF(TTM)

P/S(TTM)

I-Mab is a China-based company mainly engaged in the development of innovative global biotechnology. The Company's main businesses include engaging in track record in innovation, developing innovative drug candidates and conduct clinical validation of the assets and commercialization. The Company's pipeline is composed of ten clinical-stage assets and ten preclinical assets, among which seven assets have moved to Phase 2 or Phase 3 clinical trial stage. Its pipeline is expected to yield three near-term NDA filings and/or product launches, including felzartamab for multiple myeloma (MM), eftansomatropin alfa for pediatric growth hormone deficiency (PGHD), and potentially lemzoparlimab for myelodysplastic syndromes (MDS) and later for acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (NHL).

3 Analyst Rating

472.73% Upside

Wall Street analysts forecast IMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMAB is 5.67 USD with a low forecast of 4.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

472.73% Upside

Current: 0.990

Low

4.00

Averages

5.67

High

7.00

472.73% Upside

Current: 0.990

Low

4.00

Averages

5.67

High

7.00

HC Wainwright & Co.

Andrew Fein

Strong Buy

Maintains

$8 → $7

2025-04-04

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$8 → $7

2025-04-04

Maintains

Strong Buy

Reason

Needham

Gil Blum

Strong Buy

Reiterates

2025-04-04

Reason

Needham

Gil Blum

Price Target

2025-04-04

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

2024-11-15

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

2024-11-15

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

2024-09-17

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

2024-09-17

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

2024-08-29

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

2024-08-29

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for I-Mab (IMAB.O) is -6.00, compared to its 5-year average forward P/E of -19.87. For a more detailed relative valuation and DCF analysis to assess I-Mab 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-19.87

Current PE

-6.00

Overvalued PE

10.47

Undervalued PE

-50.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

8.46

Current EV/EBITDA

0.52

Overvalued EV/EBITDA

81.06

Undervalued EV/EBITDA

-64.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

15.38

Current PS

0.00

Overvalued PS

50.73

Undervalued PS

-19.97